Search research articles
Contact Us
Filters
Showing results (11-20 of 19) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 19 results.
Journal of Neurology
|
January 25, 2025
Three-year treatment with anti-CGRP monoclonal antibodies modifies migraine course: the prospective, multicenter I-GRAINE study
Piero Barbanti, Cinzia Aurilia, Paola Torelli, et al.
The Journal of Headache and Pain
|
November 1, 2022
Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients
Piero Barbanti, Gabriella Egeo, Cinzia Aurilia, et al.
The Journal of Headache and Pain
|
March 23, 2023
Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study
Piero Barbanti, Gabriella Egeo, Cinzia Aurilia, et al.
Journal of Neurology
|
January 17, 2024
Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study
Piero Barbanti, Cinzia Aurilia, Gabriella Egeo, et al.
Neurology and Therapy
|
March 7, 2024
Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study
Piero Barbanti, Gabriella Egeo, Stefania Proietti, et al.
Journal of Neurology
|
May 7, 2025
A 24-week prospective, multicenter, real-world study on eptinezumab's effectiveness and safety in migraine prevention (EMBRACE II)
Piero Barbanti, Cinzia Aurilia, Gabriella Egeo, et al.
The Journal of Headache and Pain
|
October 2, 2025
Profiling the real-world migraine patient: public health insights from sociodemographic, lifestyle, and clinical data in the Italian National Migraine Registry (I-GRAINE)
Piero Barbanti, Giulia Fiorentini, Cecilia Camarda, et al.
Neurology
|
January 28, 2026
Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine: 2-Year Results From the EUREkA Cohort
Edoardo Caronna, Rut Mas-de-Les-Valls, Gabriella Egeo, et al.
Cephalalgia : an International Journal of Headache
|
June 19, 2026
Is achieving higher standards in real-world migraine care feasible with anti-CGRP monoclonal antibodies preventive therapies?: Insights from the EUREkA cohort
Edoardo Caronna, Rut Mas-de-Les-Valls, Gabriella Egeo, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 19) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 19 results.
Journal of Neurology
|
January 25, 2025
Three-year treatment with anti-CGRP monoclonal antibodies modifies migraine course: the prospective, multicenter I-GRAINE study
Piero Barbanti, Cinzia Aurilia, Paola Torelli, et al.
The Journal of Headache and Pain
|
November 1, 2022
Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients
Piero Barbanti, Gabriella Egeo, Cinzia Aurilia, et al.
The Journal of Headache and Pain
|
March 23, 2023
Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study
Piero Barbanti, Gabriella Egeo, Cinzia Aurilia, et al.
Journal of Neurology
|
January 17, 2024
Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study
Piero Barbanti, Cinzia Aurilia, Gabriella Egeo, et al.
Neurology and Therapy
|
March 7, 2024
Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study
Piero Barbanti, Gabriella Egeo, Stefania Proietti, et al.
Journal of Neurology
|
May 7, 2025
A 24-week prospective, multicenter, real-world study on eptinezumab's effectiveness and safety in migraine prevention (EMBRACE II)
Piero Barbanti, Cinzia Aurilia, Gabriella Egeo, et al.
The Journal of Headache and Pain
|
October 2, 2025
Profiling the real-world migraine patient: public health insights from sociodemographic, lifestyle, and clinical data in the Italian National Migraine Registry (I-GRAINE)
Piero Barbanti, Giulia Fiorentini, Cecilia Camarda, et al.
Neurology
|
January 28, 2026
Long-Term Effectiveness and Persistence Factors of Anti-CGRP Monoclonal Antibodies in Migraine: 2-Year Results From the EUREkA Cohort
Edoardo Caronna, Rut Mas-de-Les-Valls, Gabriella Egeo, et al.
Cephalalgia : an International Journal of Headache
|
June 19, 2026
Is achieving higher standards in real-world migraine care feasible with anti-CGRP monoclonal antibodies preventive therapies?: Insights from the EUREkA cohort
Edoardo Caronna, Rut Mas-de-Les-Valls, Gabriella Egeo, et al.
Page
of 2